Evotec

About

Evotec is a drug discovery alliance company providing drug discovery solutions to pharmaceutical and biotechnology companies.

Hamburg,Hamburg,Germany
1001 - 5000
http://evotec.com

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: €7.50M
Industries: Biopharma,Biotechnology,Pharmaceutical
Founded date: Jan 1, 1993
Number Of Employee: 1001 - 5000
Operating Status: Active
Stock Symbol: nasdaq:EVO
Legal Name: Evotec AG

Evotec is a drug discovery alliance and development partnership rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licencing of innovative drug candidates, and consulting arrangements.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

10

€347.80M $519.71M

Evotec has raised a total of €347.80M $519.71M in funding over 2 rounds. Their latest funding was raised on Jan 3, 2022 from a Grant round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 3, 2022	Grant	€7.50M	1	German Federal Ministry of Education and Research (BMBF)	—	Detail
Dec 16, 2021	Grant	$18M	1	Bill & Melinda Gates Foundation	—	Detail
Nov 4, 2021	IPO	$435M	—	—	—	Detail
Oct 19, 2020	Grant	—	1	Bill & Melinda Gates Foundation	—	Detail
Oct 13, 2020	Post-IPO Equity	€250M	2	Mubadala	—	Detail

Investments

Number of Investments

Number of Lead Investments

23

5

Evotec has made 23 investments. Their most recent investment was on Dec 1, 2022, when Carrick Therapeutics raised $60M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Dec 1, 2022 Carrick Therapeutics	Series C	$60M	Biotechnology	—
Nov 29, 2022 Cajal Neuroscience	Series A	$96M	Biotechnology	—
May 3, 2022 Tubulis	Series B	€60M	Biotechnology	—
Feb 16, 2022 Centauri Therapeutics	Series A	£24M	Biotechnology	—
Feb 15, 2022 IMIDomics	Corporate Round	—	Biotechnology	Yes

Investors

Number of Lead Investors

Number of Investors

7

9

Evotec is funded by 9 investors. German Federal Ministry of Education and Research (BMBF) and Bill & Melinda Gates Foundation are the most recent investors.

Investor Name	Lead Investor	Funding Round
German Federal Ministry of Education and Research (BMBF)	Yes	Grant
Bill & Melinda Gates Foundation	Yes	Grant
Mubadala	Yes	Post-IPO Equity
CARB-X	Yes	Grant
Biotechnology Value Fund	Yes	Series Unknown
Novo Holdings	—	Post-IPO Equity
3i Group	—	Series Unknown
Gilde Healthcare	—	Series Unknown
Omega Funds	—	Series Unknown

Employee Profiles

Number of Employee Profiles

17

Evotec has 17 current employee profiles, including Executive Rudolf Rigler

Executive

Executive

Advisor

Executive

Executive

Exits

Evotec has had 3 exits. Evotec most notable exits include Forge Therapeutics , Exscientia

Date	Company Name	Exit Type	Industry
Jan 2, 2023	Forge Therapeutics	M&A	Biotechnology	Detail
Oct 1, 2021	Exscientia	IPO	Artificial Intelligence	Detail
Jul 12, 2002	Sanofi	IPO	Health Care	Detail

Acquisition

Evotec has acquired 15 organizations. Their most recent acquisition was Oxford Asymmetry International on Aug 1, 2000. They acquired Oxford Asymmetry International for 0.

Date Company Name	Industry	Acquisition Type	Price
Aug 1, 2000 Oxford Asymmetry International	Outsourcing	merge	—	Detail
Mar 6, 2005 Evotec Neurosciences	Biopharma	acquisition	—	Detail
Sep 19, 2007 Renovis	Innovation Management	acquisition	$ 152M	Detail
Aug 31, 2009 Evotec (India) Private Ltd	Biotechnology	acquisition	—	Detail
Jul 14, 2010 Develogen AG	Biotechnology	acquisition	—	Detail